Page 150 - 2019_12-Haematologica-web

F. Späth et al.
Environ Health Perspect. 2004;112(17):1691-
1696.
21. Späth F, Wibom C, Krop EJM, et al.
Biomarker dynamics in B-cell lymphoma: a longitudinal prospective study of plasma samples up to 25 years before diagnosis. Cancer Res. 2017;77(6):1408-1415.
22. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in mono- clonal gammopathy of undetermined signif- icance. N Engl J Med. 2002;346(8):564-569.
23. Delgado J, Pereira A, Villamor N, López- Guillermo A, Rozman C. Survival analysis in hematologic malignancies: recommenda- tions for clinicians. Haematologica. 2014; 99(9):1410-1420.
24. Zingone A, Kuehl WM. Pathogenesis of monoclonal gammopathy of undetermined significance (MGUS) and progression to multiple myeloma. Semin Hematol. 2011; 48(1):4-12.
25. Landgren O, Kyle RA, Rajkumar SV. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clin Cancer Res. 2011;17(6):1243-1252.
26. Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543-556.
27. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets. 2009;9(5):639-651.
28. Maehana S, Nakamura M, Ogawa F, et al.
Suppression of lymphangiogenesis by solu- ble vascular endothelial growth factor recep- tor-2 in a mouse lung cancer model. Biomed Pharmacother. 2016;84:660-665.
29. lgen U, Yayla ME, Düzgün N. Low serum fibroblast growth factor 2 levels not accom- panied by increased serum pentraxin 3 levels in patients with systemic sclerosis. Clin Rheumatol. 2017;36(2):367-372.
30. Zeineddine N, Khoury LE, Mosak J. Systemic sclerosis and malignancy: a review of current data. J Clin Med Res. 2016; 8(9):625-632.
31. Awwad RA, Sergina N, Yang H, et al. The role of transforming growth factor a in determining growth factor independence. Cancer Res. 2003;63(15):4731-4738.
32. Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35 Suppl:S185-S198.
33. Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: patho- genesis and treatments. Ann N Y Acad Sci. 2016;1364(1):32-51.
34. Brodin P, Jojic V, Gao T, et al. Variation in the human immune system is largely driven by non-heritable influences. Cell. 2015;160(1– 2):37-47.
35. Kara IO, Sahin B, Gunesacar R, Unsal C. Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-a in bone
marrow and peripheral blood of patients with multiple myeloma. Adv Ther. 2006; 23(4):635-645.
36. Lu N, Han Y, Chen T, et al. Power analysis for cross-sectional and longitudinal study designs. Shanghai Arch Psychiatry. 2013; 25(4):259-262.
37. Greipp PR, Miguel JS, Durie BGM, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005;23(15):3412- 3420.
38. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in mul- tiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-1128.
39. Kristinsson SY, Holmberg E, Blimark C. Treatment for high-risk smoldering myelo- ma. N Engl J Med. 2013;369(18):1762-1765.
40. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):538-548.
41. Fernández de Larrea C, Isola I, Pereira A, et al. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia. 2018; 32(6):1427-1434.
42. Ravi P, Kumar S, Larsen JT, et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J. 2016;6(7):e454.
2464
haematologica | 2019; 104(12)